Kosan Biosciences Incorporated, a cancer therapeutics company, focuses on developing various classes of anticancer agents through clinical development. Its product KOS-953, a Hsp90 inhibitor is in Phase III clinical trial in combination with Velcade for multiple myeloma, as well as in Phase II clinical trial in combination with Herceptin for HER2-positive metastatic breast cancer. The company's product portfolio also includes KOS-1584, an epothilone anticancer product candidate evaluated in dose-escalating Phase I clinical trial in patients with solid tumors; KOS-1803, a preclinical stage product for cancer; KOS-2187, a potent motilin receptor agonist that is in Phase I clinical testing for the treatment of GERD. In addition, Kosan Biosciences develops KOS-2464, a preclinical stage product for cancer. The company was founded in 1995 and is based in Hayward, California. As of June 25, 2008, Kosan Biosciences Incorporated operates as a subsidiary of Bristol-Myers Squibb Co.

Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. It develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. The company offers HSP90 and CNF1010 which are used for the treatment of cancer. The company was incorporated in 1999 and is based in San Diego, California

Abraxis BioScience LLC, part of Bristol Myers Squibb Co., is a company headquartered in Los Angeles, CA, involved in commercial physical and biological research.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Shanghai Renzhou Biochemical Technology Co., Ltd., established on 2003-04-23, The scope of business includes engaging in biotechnology,Technology development in the field of chemical science and technology,technical consulting,Technical Services,technology transfer,chemical reagent(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals),Glass product,Instrumentation,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals)Wholesale,retail,Own house rental. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Van Andel Institute provides biomedical research and education services. Its services include antibody production, spectral karyotyping, immunostaining and mouse modeling, animal imaging, computational biology, flow cytometry, germline modification and cytogenetics, mass spectrometry and proteomics, microarray technology, sequencing, vivarium, xenotransplantation and michigan animal consortium, as well as analytical, cellular and molecular microscopy services. The company was founded by Jay van Andel and Betty Van Andel in 1996 and is headquartered in Grand Rapids, MI.

Hangzhou Huadong Pharmaceutical Group New Drug Research Institute Co., Ltd., established on 2002-06-12, Business scope includes licensed projects:Internet Information Service for Medical Devices;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).General project:Cosmetics Wholesale;Cosmetics Retail;internet sales(Except for products that require a license for sale);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class II Medical Devices;Production of Class I Medical Devices;Sales of Class I Medical Devices;Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;Pharmaceutical special equipment sales;Remote Health Management Services;Internet of things technology research and development;R&D of industrial enzyme preparations;Technology Import and Export(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. Its operations are carried out through the Pharmaceutical and Real Estate business segments. The Pharmaceutical segment mainly manufactures and sells pharmaceuticals, medical devices and agricultural chemicals. The Real Estate segment rents real estate related to Bunkyo Green Court. The company was founded in March 1917 and is headquartered in Tokyo, Japan.

Infinity is a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, in multiple clinical studies. MARIO-275 is a global, randomized, placebo-controlled study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line and second line settings.

Pharmacia & Upjohn Co. LLC, a subsidiary of Pfizer Inc., is a company headquartered in Bingham Farms, MI, that manufactures and supplies pharmaceutical goods.

Green + Joint Stock Corp. engages in the manufacture and distribution of pharmaceutical and herbal products. The company was founded in 2016 and is headquartered in Ben Tre, Vietnam.

The Max Planck Society for the Advancement of Science (German: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.; abbreviated MPG) is a non-governmental and non-profit association of Research Institutes publicly funded by the federal and the state governments of Germany. Additionally, the Max Planck Society and its Institutes receive third party funding from public and private contributions and from the European Union. The world leading organization is named in honor of its former president, theoretical physicist Max Planck. The 86 Institutes and Research Facilities of the Max Planck Society (as of 2020) conduct basic research in the natural sciences, life sciences, social sciences, and the arts and humanities. They have a total staff of approximately 24,000 permanent employees, including 15,000 scientists, and around 5,000 non-tenured scientists and guests. As of December 31, 2018, the proportion of female employees was 44.4 percent. The Max Planck Society (with its 86 Max Planck Institutes) has a world-leading reputation as a science and technology research organization, with more than 33 Nobel Prizes awarded to its scientists, and is widely regarded as one of the foremost basic research organizations in the world.

Established in 1945, Amorepacific is Korea’s No.1 beauty company and a blue-chip corporation. Amorepacific owns nearly 30 well-known brands and has been developing rapidly worldwide. Amorepacific pays great attention to product research and development through research centers located in Korea, France, Japan and Shanghai, to develop premium and high quality skincare and cosmetics products. The Group chose Hong Kong as a strategic bridgehead for the expansion of its presence across the Greater China region and the rest of the world. Two flagship brands - LANEIGE and Sulwhasoo, were introduced in Hong Kong in 2002 and 2004 respectively. The eponymous luxury brand – AMOREPACIFIC, was introduced in Hong Kong in 2014. In 2015, ETUDE HOUSE, a playful cosmetics brand, made its debut in the territory. In 2018, the Company set foot in the personal care product market, introducing the Group’s legendary hair care brand ‘Ryo’ into Hong Kong.

Shenzhen Shengeryi Industrial Development Co., Ltd., established on 2001-05-17, Business scope includes general business items:Start a business(Specific projects will be reported separately),Economic Information Consulting,biotechnology research,to develop,domestic business,Material supply and marketing industry(Does not contain franchise,Exclusive control,Exclusives and restricted items).,The licensing program is:

Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. It operates through the following segments: Small Molecules, Biologics, Branded Formulations, and Research Services. The Small Molecules segment manufactures spanning statins, immunosuppressants, antifungals, anti-obesity, anti-diabetics, ophthalmologicals, oncologicals, and urologicals etc. The Biologics segment provides Insulins and Analogs, biosimilar Monoclonal Antibodies (MAbs), and recombinant proteins The Branded Formulation segment consists of therapeutic areas of diabetology, oncology, immunology and critical care. The Research Services segment covers Syngene development platforms. The company was founded by Kiran Mazumdar-Shaw on November 29, 1978 and is headquartered in Bangalore, India.